Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1

Interventions

Carboplatin 15Pemetrexed 8Paclitaxel 6pembrolizumab 5osimertinib 4atezolizumab 4Gemcitabine 4Erlotinib Hydrochloride 4entinostat 3durvalumab 3Cisplatin 3selpercatinib 2pralsetinib 2camrelizumab 2apatinib 2Vinorelbine 2Radiosurgery 2Nivolumab 2Injections 2Gefitinib 2Bevacizumab 2130-nm albumin-bound paclitaxel 2toripalimab 1taletrectinib 1sotorasib 1sintilimab 1repotrectinib 1pegylated granulocyte colony-stimulating factor 1patritumab 1necitumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thoracic Neoplasms × TNFSF10 protein, human × Thoracic × Clear all
NCT03083743 2017-03-20

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Shanghai Gebaide Biotechnology Co., Ltd.

Phase 3 Unknown
417 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡